DK3277725T3 - Konstante tungkædeområder med reduceret binding til FC-gammareceptorer - Google Patents
Konstante tungkædeområder med reduceret binding til FC-gammareceptorer Download PDFInfo
- Publication number
- DK3277725T3 DK3277725T3 DK16757988.7T DK16757988T DK3277725T3 DK 3277725 T3 DK3277725 T3 DK 3277725T3 DK 16757988 T DK16757988 T DK 16757988T DK 3277725 T3 DK3277725 T3 DK 3277725T3
- Authority
- DK
- Denmark
- Prior art keywords
- heavy chain
- reduced binding
- constant heavy
- chain regions
- gamma receptors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562140350P | 2015-03-30 | 2015-03-30 | |
| PCT/US2016/025051 WO2016161010A2 (en) | 2015-03-30 | 2016-03-30 | Heavy chain constant regions with reduced binding to fc gamma receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3277725T3 true DK3277725T3 (da) | 2021-01-11 |
Family
ID=56842995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16757988.7T DK3277725T3 (da) | 2015-03-30 | 2016-03-30 | Konstante tungkædeområder med reduceret binding til FC-gammareceptorer |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US10556952B2 (da) |
| EP (1) | EP3277725B1 (da) |
| JP (1) | JP6773679B2 (da) |
| AU (1) | AU2016242866B2 (da) |
| CA (1) | CA2981312C (da) |
| DK (1) | DK3277725T3 (da) |
| ES (1) | ES2846748T3 (da) |
| PL (1) | PL3277725T3 (da) |
| WO (1) | WO2016161010A2 (da) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| ES2809455T3 (es) | 2014-11-17 | 2021-03-04 | Regeneron Pharma | Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20 |
| DK3277725T3 (da) | 2015-03-30 | 2021-01-11 | Regeneron Pharma | Konstante tungkædeområder med reduceret binding til FC-gammareceptorer |
| MY195059A (en) | 2015-09-23 | 2023-01-05 | Regeneron Pharma | Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof |
| ES3009025T3 (en) | 2018-08-31 | 2025-03-25 | Regeneron Pharma | Dosing strategy that mitigates cytokine release syndrome for cd3/cd20 bispecific antibodies |
| JP2022519631A (ja) | 2019-02-12 | 2022-03-24 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 補体および標的抗原に結合する二重特異性抗体を使用するための組成物および方法 |
| EP3945800A1 (en) | 2019-04-03 | 2022-02-09 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for insertion of antibody coding sequences into a safe harbor locus |
| US20220195462A1 (en) | 2019-04-24 | 2022-06-23 | Regenxbio Inc. | Fully-human post-translationally modified antibody therapeutics |
| CN114585651A (zh) | 2019-08-08 | 2022-06-03 | 再生元制药公司 | 新型抗原结合分子形式 |
| MX2022001942A (es) | 2019-08-15 | 2022-07-27 | Regeneron Pharma | Moléculas de union a antígeno multiespecíficas para el direcciónamiento célular y usos de las mismas. |
| AU2020379735A1 (en) | 2019-11-05 | 2022-05-26 | Regeneron Pharmaceuticals, Inc. | N-terminal SCFV multispecific binding molecules |
| IL293978A (en) | 2019-12-20 | 2022-08-01 | Regeneron Pharma | New il2 agonists and methods of using them |
| KR20230009430A (ko) | 2020-05-12 | 2023-01-17 | 리제너론 파아마슈티컬스, 인크. | 신규 il10 효능제 및 그의 사용 방법 |
| CR20220660A (es) | 2020-06-03 | 2023-02-17 | Regeneron Pharma | Métodos para tratar o prevenir infecciones por sars-cov2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2 |
| US20250326861A1 (en) | 2020-09-15 | 2025-10-23 | Regenxbio Inc. | Vectorized lanadelumab and administration thereof |
| EP4214242A1 (en) | 2020-09-15 | 2023-07-26 | RegenxBio Inc. | Vectorized antibodies for anti-viral therapy |
| AU2021371307A1 (en) | 2020-10-28 | 2023-06-01 | Regenxbio, Inc. | VECTORIZED ANTI-TNF-α ANTIBODIES FOR OCULAR INDICATIONS |
| WO2022094157A1 (en) | 2020-10-28 | 2022-05-05 | Regenxbio Inc. | Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof |
| KR20230098176A (ko) | 2020-10-29 | 2023-07-03 | 리젠엑스바이오 인크. | 안구 적응증을 위한 벡터화된 tnf-알파 길항제 |
| US20230390418A1 (en) | 2020-10-29 | 2023-12-07 | Regenxbio Inc. | Vectorized factor xii antibodies and administration thereof |
| US20240309076A1 (en) | 2020-12-29 | 2024-09-19 | Regenxbio Inc. | Tau-specific antibody gene therapy compositions, methods and uses thereof |
| BR112023022878A2 (pt) | 2021-05-04 | 2024-01-23 | Regeneron Pharma | Agonistas do receptor fgf21 multiespecíficos e seus usos |
| CN117597365A (zh) | 2021-05-04 | 2024-02-23 | 再生元制药公司 | 多特异性fgf21受体激动剂及其应用 |
| AU2022314734A1 (en) | 2021-07-19 | 2024-02-08 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| CA3229369A1 (en) | 2021-08-16 | 2023-02-23 | Regeneron Pharmaceuticals, Inc. | Novel il27 receptor agonists and methods of use thereof |
| WO2023081434A2 (en) | 2021-11-07 | 2023-05-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies |
| US12559576B2 (en) | 2021-11-11 | 2026-02-24 | Regeneron Pharmaceuticals, Inc. | CD20-PD1 binding molecules and methods of use thereof |
| TW202417633A (zh) | 2022-05-03 | 2024-05-01 | 美商銳進科斯生物股份有限公司 | 用於眼適應症之載體化抗TNF-α抑制劑 |
| TW202400803A (zh) | 2022-05-03 | 2024-01-01 | 美商銳進科斯生物股份有限公司 | 載體化抗補體抗體與補體劑及其投與 |
| IL316892A (en) | 2022-05-11 | 2025-01-01 | Regeneron Pharma | Multispecific proprotein binding molecules and their uses |
| JP2025519158A (ja) | 2022-05-27 | 2025-06-24 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | インターロイキン－２プロタンパク質及びその使用 |
| CN119654338A (zh) | 2022-06-04 | 2025-03-18 | 再生元制药公司 | 白细胞介素-2蛋白质原及其用途 |
| US20240067691A1 (en) | 2022-08-18 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Interferon receptor agonists and uses thereof |
| KR20250048583A (ko) | 2022-08-18 | 2025-04-09 | 리제너론 파아마슈티컬스, 인크. | 인터페론 전구단백질 및 이의 용도 |
| US20260167741A1 (en) * | 2022-10-18 | 2026-06-18 | Crosspoint Therapeutics Inc. | Human antibody fc domain variant and use thereof |
| JP2026500017A (ja) | 2022-12-16 | 2026-01-05 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ａａｖ粒子に結合する抗原結合分子及びその使用 |
| EP4648790A1 (en) | 2023-01-12 | 2025-11-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for targeted delivery of tgfbeta |
| CN121002062A (zh) | 2023-01-13 | 2025-11-21 | 再生元制药公司 | Fgfr3结合分子及其使用方法 |
| AU2024207005A1 (en) | 2023-01-13 | 2025-08-28 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| IL322890A (en) | 2023-02-28 | 2025-10-01 | Regeneron Pharma | Multispecific molecules containing an MHC-peptide complex containing an MHC domain and an antigenic peptide and a partially targeted immune cell antigen |
| WO2024233926A1 (en) | 2023-05-10 | 2024-11-14 | Regeneron Pharmaceuticals, Inc. | Cd20-pd1 binding molecules and methods of use thereof |
| KR20260026098A (ko) | 2023-05-12 | 2026-02-25 | 리제너론 파아마슈티컬스, 인크. | 인터페론 수용체 길항제 및 이의 용도 |
| EP4727973A1 (en) | 2023-06-16 | 2026-04-22 | Regeneron Pharmaceuticals, Inc. | Cd40 x cd40 bispecific antigen-binding molecules and uses thereof |
| EP4791777A1 (en) | 2023-10-09 | 2026-08-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer with a combination of a taaxcd3 bispecific antibody and a targeted immunocytokine |
| EP4791504A1 (en) | 2023-10-09 | 2026-08-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer with a combination of a pd1 inhibitor and a targeted immunocytokine |
| KR20260113057A (ko) | 2023-11-14 | 2026-07-21 | 리제너론 파아마슈티컬스, 인크. | 조작된 중쇄 가변 도메인 및 이의 용도 |
| WO2025111473A1 (en) | 2023-11-21 | 2025-05-30 | Regeneron Pharmaceuticals, Inc. | Covalently surface modified adeno-associated virus production by in vitro conjugation, and purification of covalently surface modified adeno-associated virus |
| WO2025122614A1 (en) | 2023-12-05 | 2025-06-12 | Regeneron Pharmaceuticals, Inc. | Il18 receptor agonists and methods of use thereof |
| WO2025160340A2 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration |
| US20250242056A1 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing |
| WO2025171124A1 (en) | 2024-02-07 | 2025-08-14 | Regeneron Pharmaceuticals, Inc. | Methods of treating prostate cancer with bispecific anti-psma x anti-cd3 antibodies and bispecific anti-psma x anti-cd28 antibodies |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| US20250277048A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025199243A1 (en) | 2024-03-20 | 2025-09-25 | Regeneron Pharmaceuticals, Inc. | Trivalent multispecific binding molecules and methods of use thereof |
| WO2025199278A2 (en) | 2024-03-20 | 2025-09-25 | Regeneron Pharmaceuticals, Inc. | Masked multispecific antigen-binding molecules with cleavable linkers |
| WO2025217230A1 (en) | 2024-04-08 | 2025-10-16 | Regenxbio Inc. | Vectorized anti-complement antibodies and complement agents and administration thereof |
| WO2025240335A1 (en) | 2024-05-13 | 2025-11-20 | Regeneron Pharmaceuticals, Inc. | Fgfr3 binding molecules and methods of use thereof |
| US20250361309A1 (en) | 2024-05-24 | 2025-11-27 | Regeneron Pharmaceuticals, Inc. | Tumor-targeted split il12 receptor agonists |
| WO2025255480A1 (en) | 2024-06-07 | 2025-12-11 | Regeneron Pharmaceuticals, Inc. | Tetravalent multispecific binding molecules and methods of use thereof |
| WO2025255452A2 (en) | 2024-06-07 | 2025-12-11 | Regeneron Pharmaceuticals, Inc. | Antigen-binding molecules that bind to aav particles and uses thereof |
| US20260055171A1 (en) | 2024-06-11 | 2026-02-26 | Regeneron Pharmaceuticals, Inc. | Vegf antagonists and methods of use thereof |
| WO2026025058A1 (en) | 2024-07-25 | 2026-01-29 | Regeneron Pharmaceuticals, Inc. | Aav viral particles retargeted to egfr-expressing cancer cells |
| WO2026039325A2 (en) | 2024-08-12 | 2026-02-19 | Regeneron Pharmaceuticals, Inc. | Modified mtm1 genes and uses thereof |
| WO2026039791A1 (en) | 2024-08-16 | 2026-02-19 | Regeneron Pharmaceuticals, Inc. | Tumor-targeted split il2 receptor agonists |
| WO2026076013A1 (en) | 2024-10-01 | 2026-04-09 | Regeneron Pharmaceuticals, Inc. | Tumor-targeted il2 receptor agonists and multispecific t-cell engagers |
| WO2026112457A2 (en) | 2024-11-21 | 2026-05-28 | Regeneron Pharmaceuticals, Inc. | Heterodimeric antigen-binding molecules that bind to viral particles and uses thereof |
| WO2026136279A1 (en) | 2024-12-16 | 2026-06-25 | Regeneron Pharmaceuticals, Inc. | Engineered single domain antibody constructs and methods of use thereof |
Family Cites Families (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| JP3095168B2 (ja) | 1988-02-05 | 2000-10-03 | エル． モリソン，シェリー | ドメイン‐変性不変部を有する抗体 |
| US5057604A (en) | 1988-08-03 | 1991-10-15 | Washington University | Novel monoclonal antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| CA2065299C (en) | 1989-08-09 | 2001-07-24 | Buck A. Rhodes | Direct radiolabeling of antibodies and other proteins with technetium or rhenium |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5401629A (en) | 1990-08-07 | 1995-03-28 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Assay methods and compositions useful for measuring the transduction of an intracellular signal |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| SE507922C2 (sv) | 1996-01-31 | 1998-07-27 | Kent Karlsson | Sätt och anordning för frammatning av en doserad mängd sand |
| US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| BR9908226A (pt) | 1998-02-25 | 2000-10-24 | Lexigen Pharm Corp | Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US6926898B2 (en) * | 2000-04-12 | 2005-08-09 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| US7396917B2 (en) | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
| CA2437958C (en) | 2001-03-09 | 2018-10-30 | University Of Chicago | Polymeric immunoglobulin fusion proteins that target low-affinity fc.gamma.receptors |
| AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| JP2005510470A (ja) | 2001-09-28 | 2005-04-21 | エリューシス セラピューティクス，インコーポレーテッド | 二重特異性分子を用いた癌の予防、診断、および治療の方法ならびに組成物 |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US8673589B2 (en) | 2002-05-29 | 2014-03-18 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
| US7820166B2 (en) | 2002-10-11 | 2010-10-26 | Micromet Ag | Potent T cell modulating molecules |
| US7608260B2 (en) | 2003-01-06 | 2009-10-27 | Medimmune, Llc | Stabilized immunoglobulins |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| GB0312063D0 (en) | 2003-05-27 | 2003-07-02 | Exxonmobil Chem Patents Inc | Catalyst composition II |
| JP2007501021A (ja) | 2003-05-30 | 2007-01-25 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 遺伝子操作された定常領域を含む、抗体および融合タンパク質 |
| AU2004242845B2 (en) | 2003-05-31 | 2011-06-02 | Amgen Research (Munich) Gmbh | Human-anti-human CD3 binding molecules |
| US7700097B2 (en) | 2003-06-27 | 2010-04-20 | Biogen Idec Ma Inc. | Purification and preferential synthesis of binding molecules |
| US8399618B2 (en) | 2004-10-21 | 2013-03-19 | Xencor, Inc. | Immunoglobulin insertions, deletions, and substitutions |
| US7276585B2 (en) | 2004-03-24 | 2007-10-02 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
| WO2005100402A1 (en) | 2004-04-13 | 2005-10-27 | F.Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
| SG188175A1 (en) | 2004-06-03 | 2013-03-28 | Novimmune Sa | Anti-cd3 antibodies and methods of use thereof |
| AU2005335714B2 (en) * | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| US20120189643A1 (en) | 2004-11-30 | 2012-07-26 | Carton Jill M | Toll Like Receptor 3 Antagonists, Methods and Uses |
| AR051836A1 (es) | 2004-11-30 | 2007-02-14 | Centocor Inc | Antagonistas de receptor 3 simil toll metodos y usos |
| WO2006074399A2 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| CN102875681A (zh) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
| AU2006304387A1 (en) | 2005-10-14 | 2007-04-26 | Medimmune, Llc | Cell display of antibody libraries |
| EP2463305B1 (en) | 2006-01-12 | 2016-05-11 | Alexion Pharmaceuticals, Inc. | Antibodies to OX-2/CD200 and uses thereof |
| HUE066795T2 (hu) | 2006-03-15 | 2024-09-28 | Alexion Pharma Inc | Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral |
| EP2006380A4 (en) | 2006-03-23 | 2010-08-11 | Kyowa Hakko Kirin Co Ltd | AGONIST ANTIBODY AGAINST THE HUMAN THROMBOPOIETINE RECEPTOR |
| CA2664343C (en) | 2006-10-02 | 2016-04-26 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human il-4 receptor |
| EP2626372B1 (en) | 2007-03-29 | 2018-03-21 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| MX2009012343A (es) | 2007-05-14 | 2010-02-10 | Biogen Idec Inc | Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello. |
| CN101687933B (zh) | 2007-05-30 | 2015-11-25 | 浦项工科大学校产学协力团 | 免疫球蛋白融合蛋白 |
| AU2008255352B2 (en) | 2007-05-31 | 2014-05-22 | Genmab A/S | Stable IgG4 antibodies |
| CA2689895A1 (en) | 2007-05-31 | 2008-12-04 | Genmab A/S | Non-glycosylated recombinant monovalent antibodies |
| US20110077383A1 (en) | 2007-07-03 | 2011-03-31 | Medimmune, Llc | Hinge domain engineering |
| RU2505603C2 (ru) | 2007-09-26 | 2014-01-27 | Чугаи Сейяку Кабусики Кайся | Антитело против рецептора il-6 |
| ES2687808T3 (es) | 2007-09-26 | 2018-10-29 | Chugai Seiyaku Kabushiki Kaisha | Región constante de anticuerpo modificado |
| CA2714296A1 (en) | 2008-02-20 | 2009-08-27 | G2 Inflammation Pty Ltd | Humanized anti-c5ar antibodies |
| US20110313134A1 (en) | 2008-11-06 | 2011-12-22 | Alexion Pharmaceuticals, Inc. | Engineered antibodies with reduced immunogenicity and methods of making |
| JP5798036B2 (ja) | 2008-11-07 | 2015-10-21 | アムゲン リサーチ （ミュンヘン） ゲーエムベーハー | 小児急性リンパ芽球性白血病の新規治療 |
| AR074438A1 (es) | 2008-12-02 | 2011-01-19 | Pf Medicament | Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal |
| CA2745439C (en) | 2008-12-03 | 2019-10-15 | Genmab A/S | Antibody variants having modifications in the constant region |
| JP2012515556A (ja) | 2009-01-23 | 2012-07-12 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法 |
| TWI544077B (zh) | 2009-03-19 | 2016-08-01 | 中外製藥股份有限公司 | Antibody constant region change body |
| JP5717624B2 (ja) | 2009-03-19 | 2015-05-13 | 中外製薬株式会社 | 抗体定常領域改変体 |
| TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| US10150808B2 (en) | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
| CN102711810B (zh) | 2009-11-30 | 2015-04-22 | 詹森生物科技公司 | 效应子功能已消除的抗体Fc区突变体 |
| US20130129723A1 (en) | 2009-12-29 | 2013-05-23 | Emergent Product Development Seattle, Llc | Heterodimer Binding Proteins and Uses Thereof |
| CN102167741B (zh) | 2010-02-25 | 2014-05-14 | 上海百迈博制药有限公司 | 一种全人源抗TNF-α单克隆抗体、其制备方法及用途 |
| EP2543730B1 (en) | 2010-03-04 | 2018-10-31 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| US20130108623A1 (en) | 2010-03-29 | 2013-05-02 | Zymeworks Inc | Antibodies with Enhanced or Suppressed Effector Function |
| CA2798120A1 (en) | 2010-04-30 | 2011-11-03 | Paul P. Tamburini | Antibodies having reduced immunogenicity in a human |
| AU2011252851B2 (en) | 2010-05-14 | 2016-10-06 | The Board Of Trustees Of The Leland Stanford Junior University | Humanized and chimeric monoclonal antibodies to CD47 |
| EP2585828A4 (en) | 2010-06-25 | 2014-03-12 | Glaxo Group Ltd | METHOD FOR THE TREATMENT OF PATIENTS WITH IMMUNE SYSTEM DISEASES |
| GB201014033D0 (en) | 2010-08-20 | 2010-10-06 | Ucb Pharma Sa | Biological products |
| KR101871008B1 (ko) | 2010-09-16 | 2018-06-25 | 발리오팜 아게 | 항-huTNFR1 항체 |
| TWI736437B (zh) | 2010-11-30 | 2021-08-11 | 日商中外製藥股份有限公司 | 細胞傷害誘導治療劑 |
| SG191233A1 (en) | 2010-12-23 | 2013-07-31 | Janssen Biotech Inc | Active protease-resistant antibody fc mutants |
| LT2691417T (lt) | 2011-03-29 | 2018-10-25 | Roche Glycart Ag | Antikūno fc variantai |
| WO2013012733A1 (en) | 2011-07-15 | 2013-01-24 | Biogen Idec Ma Inc. | Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto |
| KR101870555B1 (ko) | 2011-08-23 | 2018-06-22 | 로슈 글리카트 아게 | T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법 |
| US20140370012A1 (en) | 2012-01-27 | 2014-12-18 | Gliknik Inc. | Fusion proteins comprising igg2 hinge domains |
| SG10201704846VA (en) | 2012-03-14 | 2017-07-28 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| WO2013157105A1 (ja) | 2012-04-18 | 2013-10-24 | 公立大学法人大阪市立大学 | ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用 |
| WO2013163427A1 (en) * | 2012-04-25 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibodies to treat hiv-1 infection |
| JO3820B1 (ar) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
| SG10201609535TA (en) | 2012-06-05 | 2017-01-27 | Regeneron Pharma | Methods for making fully human bispecific antibodies using a common light chain |
| BR112015000798A2 (pt) | 2012-07-13 | 2017-06-27 | Zymeworks Inc | heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3 |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| BR112015006824A2 (pt) | 2012-09-27 | 2017-07-04 | Merus B V | anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico |
| WO2014054804A1 (ja) | 2012-10-05 | 2014-04-10 | 協和発酵キリン株式会社 | ヘテロダイマータンパク質組成物 |
| MX2015003616A (es) | 2012-10-08 | 2015-06-05 | Roche Glycart Ag | Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de uso. |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| KR102813816B1 (ko) | 2013-07-05 | 2025-05-29 | 젠맵 에이/에스 | 인간화 또는 키메라 cd3 항체 |
| BR112016000666A2 (pt) | 2013-07-12 | 2017-10-03 | Zymeworks Inc | Constructos de ligação de antígeno cd3 e cd19 biespecíficos |
| HUE050159T2 (hu) | 2013-12-17 | 2020-11-30 | Genentech Inc | Anti-CD3 antitestek és alkalmazási eljárások |
| JP6510532B2 (ja) | 2013-12-20 | 2019-05-08 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性ｈｅｒ２抗体及び使用方法 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| DK3277725T3 (da) | 2015-03-30 | 2021-01-11 | Regeneron Pharma | Konstante tungkædeområder med reduceret binding til FC-gammareceptorer |
| GB201506407D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| JOP20160154B1 (ar) | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
| MY195059A (en) | 2015-09-23 | 2023-01-05 | Regeneron Pharma | Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof |
| ES2954153T3 (es) | 2015-12-22 | 2023-11-20 | Regeneron Pharma | Combinación de anticuerpos anti-PD-1 y anticuerpos biespecíficos anti-CD20/anti-CD3 para tratar el cáncer |
| TW201815821A (zh) | 2016-07-18 | 2018-05-01 | 美商再生元醫藥公司 | 抗茲卡病毒抗體及使用方法 |
| KR102520731B1 (ko) | 2016-09-23 | 2023-04-14 | 리제너론 파아마슈티컬스, 인크. | 항-steap2 항체, 항체-약물 컨쥬게이트, 및 steap2 및 cd3에 결합하는 이중특이적 항원-결합 분자, 및 이의 용도 |
| KR102531251B1 (ko) | 2016-09-23 | 2023-05-15 | 리제너론 파아마슈티컬스, 인크. | 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체 |
| TW202504917A (zh) | 2018-06-21 | 2025-02-01 | 美商再生元醫藥公司 | 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症之方法 |
| ES3009025T3 (en) | 2018-08-31 | 2025-03-25 | Regeneron Pharma | Dosing strategy that mitigates cytokine release syndrome for cd3/cd20 bispecific antibodies |
| KR20230047214A (ko) | 2019-07-26 | 2023-04-06 | 벨로3디, 인크. | 3차원 물체 형상화에 대한 품질 보증 |
| MX2022001942A (es) | 2019-08-15 | 2022-07-27 | Regeneron Pharma | Moléculas de union a antígeno multiespecíficas para el direcciónamiento célular y usos de las mismas. |
-
2016
- 2016-03-30 DK DK16757988.7T patent/DK3277725T3/da active
- 2016-03-30 AU AU2016242866A patent/AU2016242866B2/en active Active
- 2016-03-30 ES ES16757988T patent/ES2846748T3/es active Active
- 2016-03-30 JP JP2017551033A patent/JP6773679B2/ja active Active
- 2016-03-30 WO PCT/US2016/025051 patent/WO2016161010A2/en not_active Ceased
- 2016-03-30 US US15/562,881 patent/US10556952B2/en active Active
- 2016-03-30 EP EP16757988.7A patent/EP3277725B1/en active Active
- 2016-03-30 PL PL16757988T patent/PL3277725T3/pl unknown
- 2016-03-30 CA CA2981312A patent/CA2981312C/en active Active
-
2019
- 2019-12-19 US US16/720,623 patent/US11518807B2/en active Active
-
2022
- 2022-10-06 US US17/961,442 patent/US12509516B2/en active Active
-
2025
- 2025-11-24 US US19/398,850 patent/US20260085116A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016161010A2 (en) | 2016-10-06 |
| WO2016161010A3 (en) | 2016-11-10 |
| EP3277725B1 (en) | 2020-11-25 |
| US12509516B2 (en) | 2025-12-30 |
| JP6773679B2 (ja) | 2020-10-21 |
| JP2018512420A (ja) | 2018-05-17 |
| US20200109203A1 (en) | 2020-04-09 |
| HK1250039A1 (zh) | 2018-11-23 |
| CA2981312C (en) | 2023-09-26 |
| US20180282411A1 (en) | 2018-10-04 |
| US20230287117A1 (en) | 2023-09-14 |
| CA2981312A1 (en) | 2016-10-06 |
| US10556952B2 (en) | 2020-02-11 |
| PL3277725T3 (pl) | 2021-06-14 |
| ES2846748T3 (es) | 2021-07-29 |
| AU2016242866B2 (en) | 2021-06-03 |
| AU2016242866A1 (en) | 2017-10-26 |
| US20260085116A1 (en) | 2026-03-26 |
| US11518807B2 (en) | 2022-12-06 |
| EP3277725A2 (en) | 2018-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3277725T3 (pl) | Regiony stałe łańcucha ciężkiego o zmniejszonym wiązaniu do receptorów Fc gamma | |
| IL259173A (en) | Ctla4 binders | |
| CL2018000370A1 (es) | Nuevos anticuerpos anti-pd-1 | |
| PL3328894T3 (pl) | Przeciwciała dla il2rbeta/wspólnego łańcucha gamma | |
| IL251524A0 (en) | T cell receptors | |
| BR112017001385A2 (pt) | anticorpos anti-pd-1 | |
| HUE051496T2 (hu) | TL1A-hoz specifikusan kötõdõ ellenanyagok | |
| DK3334824T3 (da) | Pd-1-antistoffer | |
| DK3912987T3 (da) | Oprensningsplatform til bispecifikke antistoffer | |
| PL3126383T3 (pl) | Zmodyfikowany łańcuch J | |
| HUE048667T2 (hu) | AXL-hez kötõdõ ellenanyagok | |
| DK3218406T3 (da) | Bindingsmolekyler, der er specifikke for cd73, og anvendelser deraf | |
| DK3228566T3 (da) | Indretning til at vælge genstande | |
| DK3206535T3 (da) | Ligevægtsledforbindelse | |
| EP3369944A4 (en) | HYDRAULIC DEVICE | |
| DK3411268T3 (da) | Anordning til at bære last | |
| HUE047455T2 (hu) | HPA-1A elleni antitestek | |
| FI20145379A7 (fi) | Torrefiointilaite | |
| DK3233915T3 (da) | Antistoffer til il-17c | |
| NO344137B1 (no) | Selvjusterende hivkompensator | |
| DK3259407T3 (da) | Hydraulisk indretning | |
| FR3020302B3 (fr) | Tronconneuse | |
| FI20155401A7 (fi) | Tienrakennusmassan levityslaite | |
| DK3078848T3 (da) | Belastningskompensationsindretning | |
| ES1141490Y (es) | Mochila |